New Deadline for Nitrosamine Impurities

26.03.2020
Risk Evaluation: Extension of Deadline for CEP-Holders until 31.July 20 and for MAH (Marketing Authorisation Holders) until 1.October 2020

The deadline of 26.03.20 to complete step 1 (Risk evaluation) was extended for MAHs and for CEP-Holders due to due to major challenges in meeting the deadlines and due to COVID-19 pandemia.

For further information:



Are you still working on your risk assessment and do you need professional support?

Then, contact us at info@horn-pharma.de.

We know the details of these new requirements. We help you with your CEPs, DMFs and Marketing Authorizations. You can benefit from our long term-experience.


Back

HOTLINE

Phone +49 (0) 7251/305 529
Fax +49 (0) 7251/305 528
Mail

Events

  • 25.08.2022
    Online Seminar: Prozessvalidierung - Aktuelle Anforderungen an CMC-Daten
    More
  • 10.11.2022
    Verunreinigungen in Arzneimitteln - Fokus Nitrosamine
    More
  • 15.11.2022
    MEGRA StartUp
    More
Get all events



News

  • 16.05.2022
    New Clinical Trials Regulation and new IMPD-Guidelines in place
    More
  • 29.10.2020
    Latest Guidances regarding Nitrosamine Impurities
    More
  • 18.05.2020
    Impact of COVID-19 pandemic on Pharma: GMP and Regulatory Flexibility
    More
Get all news